MRM (MEDIROM Healthcare Technologies) EBITDA: $2.05 Mil (TTM As of Jun. 2025)


MRM MEDIROM Healthcare Technologies Inc MRM
53 GF Score
Price $1.07
GF Value $4.08
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MEDIROM Healthcare Technologies EBITDA?

MEDIROM Healthcare Technologies MRM -4.43% 53 EBITDA is $2.05 Mil as of Jun. 2025. GuruFocus rates MRM with a GF Score™ of 53/100 and a GF Value™ of $4.08 (Possible Value Trap). The stock has 8 warning signs investors should review.

MEDIROM Healthcare Technologies's EBITDA for the six months ended in Jun. 2025 was $-2.86 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $2.05 Mil.

During the past 12 months, the average EBITDA Growth Rate of MEDIROM Healthcare Technologies was 42.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of MEDIROM Healthcare Technologies was 48.40% per year. The lowest was 48.40% per year. And the median was 48.40% per year.

MEDIROM Healthcare Technologies's EBITDA per Share for the six months ended in Jun. 2025 was $-0.36. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.36.

During the past 12 months, the average EBITDA per Share Growth Rate of MEDIROM Healthcare Technologies was 65.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of MEDIROM Healthcare Technologies was 42.20% per year. The lowest was 42.20% per year. And the median was 42.20% per year.

MEDIROM Healthcare Technologies  (NAS:MRM) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


MEDIROM Healthcare Technologies EBITDA Related Terms


MEDIROM Healthcare Technologies EBITDA Historical Data

* Premium members only.

The historical data trend for MEDIROM Healthcare Technologies's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEDIROM Healthcare Technologies EBITDA Chart

MEDIROM Healthcare Technologies Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA
Get a 7-Day Free Trial -5.31 -2.43 2.77 2.15 2.52

MEDIROM Healthcare Technologies Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.65 3.78 -2.33 4.91 -2.86

MRM vs DROR, CLIK, EJH: EBITDA Comparison

For the Personal Services subindustry, MEDIROM Healthcare Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEDIROM Healthcare Technologies EV-to-EBITDA vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MEDIROM Healthcare Technologies's EV-to-EBITDA falls into.


MRM
53GF Score
MEDIROM Healthcare Technologies Inc MRM
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MEDIROM Healthcare Technologies's EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

MEDIROM Healthcare Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2024, MEDIROM Healthcare Technologies's EBITDA was $2.52 Mil.

MEDIROM Healthcare Technologies's EBITDA for the quarter that ended in Jun. 2025 is calculated as

MEDIROM Healthcare Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2025, MEDIROM Healthcare Technologies's EBITDA was $-2.86 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $2.05 Mil mean?
MEDIROM Healthcare Technologies (MRM) has a EBITDA of $2.05 Mil as of Jun. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on MEDIROM Healthcare Technologies.
Is MEDIROM Healthcare Technologies' EBITDA too high?
MEDIROM Healthcare Technologies' current EBITDA is $2.05 Mil. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' EBITDA compare to DROR and CLIK?
MEDIROM Healthcare Technologies' EBITDA of $2.05 Mil can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Personal Services company?
A good EBITDA depends on the Personal Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on MEDIROM Healthcare Technologies. MEDIROM Healthcare Technologies's current EBITDA is $2.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.08, compared to a current price of $1.07 — trading 73.8% below its estimated fair value. The current EBITDA is $2.05 Mil. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current EBITDA is $2.05 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?

Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued. The current stock price of $1.07 is trading 73.8% below its estimated GF Value™ of $4.08. GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.

Key valuation signals for MRM:

  • EBITDA: $2.05 Mil
  • GF Value™: $4.08 vs. price of $1.07 (73.8% below fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MEDIROM Healthcare Technologies Business Description

Address 2-3-1 Daiba, 16th Floor, Tradepia Odaiba, Minato-ku, Tokyo, JPN, 135-0091
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score

Get the complete analysis for MRM

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$4.08
GF Value